What’s new

• Consolidated net loss hit ₹71 cr in Q4 against a ₹13 cr profit a year ago.
• Full-year consolidated profit climbed to ₹310 cr from ₹12 cr.
• Standalone operations posted a full-year loss of ₹104 cr.

Why it matters

The gap between surging consolidated revenue and the standalone bottom-line loss points to heavy reliance on subsidiaries. While the group looks fast-growing on paper, the Q4 reversal suggests that aggressive scaling comes with significant cost pressures. Investors are left to decide whether these losses are a feature of expansion or a structural problem.

What we’re watching

• Whether standalone losses widen in FY27.
• Cost management initiatives to restore group-level margins.
• The sustainability of subsidiary-led earnings growth.

The full read

Fischer Medical Ventures delivered a year of extreme contrasts. While consolidated revenue for the year ending March 31, 2026, surged to ₹3,086 crore—nearly triple the ₹1,107 crore reported in FY25, the company’s profitability hit a wall. A consolidated full-year net profit of ₹310 crore looks promising, but that figure masks a deeper issue. The fourth quarter ended in a ₹71 crore net loss. Even more concerning is the standalone performance, which swung from a ₹6.6 crore profit to a ₹104 crore loss over the same period. The board has opted for a conservative dividend of 5 paise per share. The core issue is the divide between high-growth consolidated revenues and the struggling standalone entity. Scaling subsidiaries has clearly swelled the top line, yet the rising expense profile in Q4 suggests that growth is becoming expensive. The company is at a junction where it must reconcile these ballooning costs with its expansion goals.

Primary source: BSE · NSE